Numbers alone don't tell the story. But they confirm it.
| Metric | Value |
|---|---|
| Years of continuous research | 25+ |
| Global patents | 78 |
| Peer-reviewed publications | 50+ |
| Families served | 200,000+ |
| R&D investment | $25M+ |
The major milestones in ABTIDE's research and commercial history: from the first Gold-Ratio patent to 200,000 families served and 78 global patents.
Over a decade of scientific innovation, clinical validation, and global expansion
Launched amino acid research initiative with focus on bioavailability optimization
Filed foundational patent for Gold Ratio amino acid formulation technology
Established partnerships with leading research institutions across North America and Asia
Completed first human clinical trials demonstrating 95% absorption rate
Integrated L-Ergothioneine research into longevity science division
Launched international distribution network across 15+ countries
Unveiled ABTIDE Wellness with complete product ecosystem and Vancouver HQ
Launched amino acid research initiative with focus on bioavailability optimization
Filed foundational patent for Gold Ratio amino acid formulation technology
Established partnerships with leading research institutions across North America and Asia
Completed first human clinical trials demonstrating 95% absorption rate
Integrated L-Ergothioneine research into longevity science division
Launched international distribution network across 15+ countries
Unveiled ABTIDE Wellness with complete product ecosystem and Vancouver HQ
Numbers alone don't tell the story. But they confirm it.
| Metric | Value |
|---|---|
| Years of continuous research | 25+ |
| Global patents | 78 |
| Peer-reviewed publications | 50+ |
| Families served | 200,000+ |
| R&D investment | $25M+ |
| Year | Milestone |
|---|---|
| 2012 | ABTIDE Laboratory established in Vancouver, Canada. Research program initiated under the direction of Dr. Robert R. Wolfe. The founding principle: no peer-reviewed evidence, no product. |
| 2014 | Gold-Ratio essential amino acid formula patented. The precise proportional composition of nine essential amino acids for optimal muscle protein synthesis — the scientific foundation of our entire amino acid series — receives its first legal protection. |
| 2015 | Flash-dissolve absorption technology developed and validated. Bioavailability rates exceeding 95% achieved for free-form essential amino acid delivery — compared to 60–70% for standard protein supplementation. |
| 2016 | Formal research collaboration established with Tract Lab Canada. The 42-strain probiotic development program begins. Gold Shield™ 6-layer encapsulation technology enters development. |
| 2018 | Complete methylation management research program launched. Ergothioneine and epigenetics intersection investigation begins. First global patents filed in cellular nutrition and DNA methylation support. |
| 2020 | 12 global patents granted in epigenetics and cellular nutrition. Total portfolio reaches 64 patents. The L-Ergothioneine Ultra formula receives its complete formulation protection. |
| 2023 | Full international commercial launch. 200,000 families reached. 78 patents. 50+ peer-reviewed publications. The research program that began in 2012 becomes the platform that serves a global community. |
| Now | Current investigation programs in metabolomics, personalized nutrition, and longevity biomarker intervention are underway. We don't announce until we can deliver. |
The next 25 years of ABTIDE research will focus on the intersection of genomics, microbiome science, and precision nutrition — a domain where the science is advancing faster than the commercial nutritional infrastructure can currently address.
We're building the infrastructure.
ABTIDE — Built for Tomorrow Developed in Vancouver, Canada
Ready to Begin Your Protocol?
25 years of research · 78 global patents · Formulated for you.